The aim of this study was to identify the most favorable H2RA (H2 receptor antagonist) for the treatment of upper gastrointestinal hemorrhage (non-phlebeurysm). A decision tree was constructed to evaluate cost-effectiveness among an existing treatment (control), roxatidine, famotidine and ranitidine from the viewpoints of the payer and the medical facility . Clinical parameters used as transition probabilities were obtained from the results of the domestic RCT (Randomized Controlled Trial) of each drug. The cost items consisted of the direct medical cost, capital cost , and medical staff (doctors and nurses) personnel costs. The time horizon was set at 12.3 days on average and there was therefore no discount. Of the three drugs, at approximately 140,000 yen less than the control, ranitidine was estimated to be most cost-saving for the payer . In percentage terms, ranitidine had the highest earnings rate among the H2RAs of 46 .0% and roxatidine had the highest earnings in money terms among the H2RAs of approximately 120 ,000 yen. A one-way sensitivity analysis used for investigating extra periods of hospitalization showed that this had no impact on the base case. A two-way analysis showed that ranitidine had the highest efficiency of about 55 % for the cases analyzed. When a threshold analysis was conducted , it was found that, while there would be no change in the hemostatic rate in substitutive plans, the hemostatic rate of 0 .60 for famotidine (ceiling total cost : 375,801 yen) and that of 0.61 for ranitidine (ceiling total cost : 406,271 yen) were the thresholds affecting the results of analysis. It is therefore likely that selecting ranitidine first in preference to roxatidine or famotidine would be more cost-effective.
Introduction
The importance of evidence-based medicine (EBM) has recently been increasing in the field of healthcare as the quality and cost of medical care is of paramount concern for those being treated. In Japan, under the directions given by the Ministry of Health, Labor and Welfare (MHLW), university and national hospitals have introduced the flat-sumpayment-system (Matsuda S. Executive summary report of research on use of Diagnosis Procedure Combination ; DPC in acute hospital secondary care. March 2003. http : //webabst.niph.go.jp/) based on the DPC for hospitalized care, in an attempt to standardize healthcare quality and improve transparency.
Asagi et al1). and Takahashi et al2). reported that upper
gastrointestinal hemorrhage is primarily caused by peptic ulcer disease, which accounts for approximately 60% of all patients with the hemorrhage ; the second predominant cause is acute gastric mucosal lesion (AGML), accounting for approximately 20% of all cases. The seriousness of upper gastrointestinal bleeding should not be underestimated ; particularly in light of the stressful events and experiences that are part of modern life.
In the treatment of upper gastrointestinal hemorrhage, endoscopy is usually performed to confirm bleeding lesions and status so as to determine if the bleeding is related to phlebeurysm or not. Based on the endoscopic findings obtained, a therapeutic strategy is devised. Non-phlebeurysmrelated bleedings usually require pharmacotherapy ; endoscopic hemostasis using a hemostatic clip or pure ethanol injection is followed by drug treatment. The drugs frequently used are Proton Pump Inhibiters (PPIs) and H2 receptor antagonists (H2-blockers ; H2RAs), and it has been proven that the hemostatic rate achieved three days after the start of drug treatment is approximately 70-90%3-6), One of the PPIs is reported to achieve a hemostatic rate as high as 90%7), however its price is up to four times greater than H2RAs , which precludes smooth and immediate decision-making to use PPIs. Of the H2RAs (which have comparable in hemostatic rates) famotidine is widely used in Japan because it is well known. Famotidine costs 403 Japanese Yen (based on the National Health Insurance Price in April 2003) and is the most expensive H2RAs available for the treatment of upper gastrointestinal hemorrhage in Japan. On the other hand cimetidine is a first launched H2RA in not only Japan but also Worldwide. It was a best alternative as a control for the economic analysis as its brand product is available at the lowest price in H2RA in Japan.
As the treatment of upper gastrointestinal hemorrhage requires the use of a significant amount of medication at our hospital, we performed an EBM-aided investigation to identify the most favorable H2RA for the treatment of upper gastrointestinal hemorrhage (non-phlebeurysm) with the aim of reducing these drug costs, both from a payer and institutional perspective.
Methods

Preparation of a decision tree model
A simple decision tree model was constructed based on the usual treatment offered for upper gastrointestinal hemorrhage in our hospital in order to be employed to evaluate cost-effectiveness among H2RAs as shown at Fig. 1 . The hypothetical 10,000 cohort on the model shows stochastic transitions in the following drug groups : an existing treatment (control) group (cimetidine data were quoted), roxatidine group, famotidine group and ranitidine group. Generally a decision node (box) allows a decision-maker to be administrated four H2RA therapies. After choosing each of H2RA 
Clinical parameters
To obtain the transition probabilities that are the rate of hemostasis (hemostatic rate) and the recurrence rate for the individual drugs included in the decision model, the hemostatic rate (primary evaluation time point : after 36 hrs) and the recurrence rate (after 72 hrs) for cimetidine were obtained from the results of domestic randomized controlled trials (RCT) which compared each drug with cimetidine The cimetidine hemostasis rate at the observation time (36 hrs =1.5 days) was calculated from the hemostasis rate, using the formula (1) where P is the probability of hemostasis with H2RAs other than cimetidine, S(t) is the probability obtained for, RR is the relative risk. (where AF5,4% is the annuity factor for 5 years at an interest rate of 4 percentage) For more information upon calculation of NPV of an endoscopy equipment, a new article price was set at 15 million yen and a resale price, at 900,000 yen based on catalogues of OLYMPUS CORPORATION. On the other hand upon calculation of NPV of a bed, a new article price was set at 268,000 yen and a resales price, at zero yen, based on catalogues of Komatsu Ika Kogyo Co. LTD.
Cost parameters
Setting of other conditions
As showed at Fig. 2 the time horizon of the present analysis was set to be 12.7 days on average including additional hospitalization, therefore no discount was made. In Table 2 . Cost Items to be Included in Analysis.
addition, the present analysis was performed from the viewpoints of the payer and the medical facility. The analysis software used was DATA 3.5 (Tree Age Software, Inc., Williamstown, MA) and Microsoft Excel 2000 (Microsoft Corporation, Redmond, WA).
Sensitivity analysis (Confirmation of robustness)
Generally sensitivity analyses should be undertaken for testing over the range of variables of plausible values in order to gain robustness of the base case result. There are many different ways of testing variables in a sensitivity analysis.
Upon performing the sensitivity analysis, the variables requiring the sensitivity analysis were identified by drawing a tornado diagram, called a tornado analysis. Because the book by Muenning P14) stated a tornado analysis is a handy way of determining how much influence each of the variables has on the overall model as the overall influence of the variables on the cost or effectiveness of a particular strategy is not easy to predict. It also stated the extent to which a variable can influence the dominance of each strategy in a decision analysis model is determined by : 1) the overall magnitude of the variable, 2) uncertainty associated with the baseline value of the variable, 3) the relative position of the variable in a decision arm, and 4) the number of decision arms in which the variable appears. Based on the results of the tornado analysis, first a oneway sensitivity analysis was performed when varying extra period of hospitalization with the range from 3.40 to 15.20 days. Secondly a two-way sensitivity analysis was carried out because the hemostatic rates of famotidine and ranitidine 
Cost analysis (base case)
A result of a cost analysis for the base case was shown at Table 3 .
Ranitidine was estimated to save costs most for the three cost components (total cost, medical earnings and medical practice cost), compared with existing therapies. However, when the relationship between earnings and costs was studied, cimetidine (existing therapy) was most profitable of 141,582 yen (reduction rate : 27.8 %). Of the three other drugs evaluated, roxatidine was estimated to be the most profitable of 117,983 yen and famotidine was least profitable of 101,600 yen. Furthermore, as shown at Table 3 , when earnings rate in each of H2RAs was computed ranitidine had the highest rate of 46.0% and roxatidine, the lowest one of 39.0 % in H2RAs. In arguing on balance of reduction rate between medical practice earnings and its costs, the cost re- In addition, the threshold analysis showed at Table 4 that, where there would be no change in the homeostatic rate in substitutive plans, the homeostatic rate of 0.60 for famotidine and 0.61 for ranitidine were the thresholds affecting the results of analysis. The aforementioned result was interpreted that if the hemostatic rate for famotidine was constantly gained less than 0.60, ratididine was cost-effectively dominant to famotidine. For more information the cross point of cost for famotidine was 375,801 yen, one for ranitidine 406,271 yen.
Discussion
In Japan, the EBM-Based Guideline for Treatment of Gastric Ulcer Disease (developed as part of the MHLW' s total program on scientific research promotion and healthcare technology evaluation) has recently been published as a guiding principle for the treatment of gastric ulcer disease. The Guideline recommends PPIs as the first line of drug therapy ; and since 90% of patients with gastric ulcer disease are infected with Helicobacter pylofi, a PPI-based combination regimen with two antibiotics (AMOX and CAM) is recommended for eradication of H. pylori. A meta-analysis performed by DiMario et al15). proved a significant advantage for a PPI (omeprazole) over H2RAs (odds ratio = 2.00, 95 % confidence interval 1.57-2.55). For H2RAs, the Guideline clearly states that "if PPIs cannot be used, then H2RAs which are next to the PPIs in efficacy will be used." Accordingly, PPIs (note that in Japan, only omeprazole has ob- tamed an official approval for an injection formulation) would normally be selected. However, since PPIs are 1.7 to 4 times higher in price than H2RAs, it is not an easy decision to use PPIs when considering the consumption of healthcare resources. In this study, we first investigated costeffectiveness of H2RAs and then linked the investigation to evaluation of PPIs and H2RAs.
A PubMed (in English) and Japan Centra Revno Medicina (for medical journals written in Japanese) search was performed to identify clinical parameters for H2RAs which were required for analyses. In overseas, a large number of RCTs of ranitidine were found, whereas RCTs of famotidine and roxatidine were rarely found. In Japan, head-to-head RCTs among H2RAs were not frequently carried out. We therefore decided to identify clinical parameters specific to Japan, and while utilizing a random effect model, a frequently used model in meta-analyses, we only used the domestic RCT results to try to estimate clinical parameters to be incorporated into a decision tree model. This estimation revealed no significant differences in hemostatic rates among cimetidine , ranitidine, famotidine and roxatidine, and suggested no differences in clinical efficacy among the H2RAs. The metaanalysis performed by Di Mario et al. 15 ) indicated that when the endpoint was a healing rate of peptic ulcer disease 4-6 weeks after the start of treatment, no significant differences were noted among H2RAs (cimetidine, ranitidine and famotidine) in the endpoint.
In the present study, a simulation analysis was performed than the existing therapy, whereas the difference between earnings and costs from the viewpoint of a medical institution was slightly smaller for ranitidine than roxatidine. On the other hand, roxatidine was also the least costly, although to a smaller extent, in all three cost components evaluated when compared to the existing therapy, whereas the difference between earnings and costs was greater. Famotidine was located between ranitidine and roxatidine. The cost reduction produced by the three drugs when compared to the existing therapy was primarily attributable to the smaller number of extended hospitalizations required for symptom aggravation and/or additional endoscopy. Finally ranitidine had the highest earnings rate in H2RAs from the institutional viewpoint. Because earnings' reduction was larger than cost reduction in ranitidine, whereas the earnings' reductions, smaller than the costs' reductions in both roxatidine and famotidine. A tornado diagram was drawn to identify confounding factors that substantially affect analysis results, and by varying the confounding factors a sensitivity analysis was carried out. For extra hospitalization, no impact was found on the base case result. A two-way sensitivity analysis in which the hemostatic rates of ranitidine and famotidine were made to vary simultaneously revealed that the hemostatic rate of an H2RA substantially affected the result. It was considered, however, to be more likely that ranitidine would be more cost-effective than famotidine. It was therefore expected that the present analysis might provide a basis for decisionmaking for selecting drugs. All patients do not always follow the simulation model evaluated in this study, and the analysis used in this study has limitations from the viewpoint of individual patients. It may be required to compare the analysis results against clinical practices at our hospitals to evaluate transferability and generalizability16) of the analysis results, and in addition, to investigate the costeffectiveness of H2RAs and PPIs in the treatment of upper gastrointestinal hemorrhage.
In the future, as pharmacists put EBM into practice, it is expected that they will not only to explore evidence available through publication, but also create their own new evidence using information surrounding them in order to resolve problems confronting them.
In conclusion, as describe above we take into consideration that the present analysis is a proper method of evaluating the three drugs. It is likely that selecting ranitidine first 
